APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics shares jumped ~20% after 52-week Phase II Part A data showed sustained efficacy for its AD candidate zumilokibart, highlighting durable responses and the advantage of infrequent dosing. The results materially enhance the drug's clinical profile and likely increase probability of continued development and heightened investor interest.

Analysis

Apogee Therapeutics shares jumped ~20% after 52-week Phase II Part A data showed sustained efficacy for its AD candidate zumilokibart, highlighting durable responses and the advantage of infrequent dosing. The results materially enhance the drug's clinical profile and likely increase probability of continued development and heightened investor interest.